Chemical Communications, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
This feature article provides a detailed overview of the synthesis, properties and applications sydnonimines, fascinating compounds from mesoionic familly.
Язык: Английский
Nature Chemistry, Год журнала: 2024, Номер 16(8), С. 1348 - 1356
Опубликована: Апрель 1, 2024
Язык: Английский
Процитировано
27
Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)
Опубликована: Янв. 2, 2025
Abstract Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for diagnosis and treatment multiple diseases. Radiopharmaceutical therapy, which directly causes systematic irreparable damage cells, has attracted increasing attention in refractory diseases that are not sensitive current therapies. As Food Drug Administration (FDA) approvals [ 177 Lu]Lu-DOTA-TATE, Lu]Lu-PSMA-617 their complementary diagnostic agents, namely, 68 Ga]Ga-DOTA-TATE Ga]Ga-PSMA-11, radiopharmaceutical-based theranostics (radiotheranostics) being increasingly implemented clinical practice oncology, lead a new era radiopharmaceuticals. The generation radiopharmaceuticals utilizes targeting vector achieve accurate avoid off-target deposition, making it possible improve efficiency biosafety tumour therapy. Numerous studies have focused on developing novel broader range disease targets, demonstrating remarkable vivo performance. These include high tumor uptake, prolonged retention time, favorable pharmacokinetic properties align with standards. While radiotheranostics been widely applied applications now expanding neurodegenerative diseases, cardiovascular inflammation. Furthermore, radiotheranostic-empowered precision medicine is revolutionizing cancer paradigm. Diagnostic play pivotal role patient stratification planning, leading improved therapeutic outcomes radionuclide This review offers comprehensive overview evolution radiopharmaceuticals, including both FDA-approved clinically investigated explores mechanisms cell death induced by It emphasizes significance future prospects theranostic-based advancing medicine.
Язык: Английский
Процитировано
15
Advanced Materials, Год журнала: 2024, Номер 36(33)
Опубликована: Июнь 17, 2024
The development of bioorthogonal activation in drug release represents a promising avenue for precise and safe anticancer treatment. However, two significant limitations currently hinder their clinical application: i) the necessity separate administration precursor its corresponding activator, leading to poor accumulation potential side effects; ii) reliance on exogenous metal or organic activators triggering activation, which often exhibit low efficiency systemic toxicity when extending living animals. To overcome these limitations, nitric oxide (NO)-mediated codelivery nanoassembly, termed TTB-NH
Язык: Английский
Процитировано
10
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Янв. 22, 2025
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while mitigating off-target effects normal tissues, the concept of prodrug-based bispecific has emerged. This review delineates various mechanisms underlying action antibodies, including protease-mediated activation, steric hindrance release via proteolytic processing, activation by soluble factors, conditional assembly, and chain exchange-mediated activation. We also address critical challenges that must be overcome optimize development clinical application these sophisticated agents.
Язык: Английский
Процитировано
2
Macromolecular Rapid Communications, Год журнала: 2025, Номер unknown
Опубликована: Апрель 4, 2025
Targeted protein degradation (TPD) using the proteolysis-targeting chimeras (PROTACs) is emerging as a revolutionary technology, offering potential strategy for cancer treatment by inducing of overexpressed oncogenic proteins in tumors. PROTACs function recruiting E3 ligases and utilizing ubiquitin-proteasome pathway (UPS) to catalyze target proteins. Compared traditional small molecules inhibitors, exhibit enhanced selectivity, ability overcome drug resistance, traditionally deemed "undruggable". However, poor water solubility low cellular permeability significantly limit their pharmacokinetic properties, while systemic toxicity may hinder clinical application. To address these limitations, strategies that integrate with delivery systems are gaining attention. This review summarizes latest advancements various enhance vivo efficacy reduce off-target effects PROTACs, including prototype nanoparticles, covalent modification-based prodrug strategies, innovative multi-headed designs, microneedle systems, discussing design principles associated challenges. The combination potent multifunctional holds promise accelerating translation improving therapeutic treatment.
Язык: Английский
Процитировано
1
International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 4021 - 4040
Опубликована: Май 1, 2024
Abstract: Cataract is a leading cause of blindness globally, and its surgical treatment poses significant burden on global healthcare. Pharmacologic therapies, including antioxidants protein aggregation reversal agents, have attracted great attention in the cataracts recent years. Due to anatomical physiological barriers eye, effectiveness traditional eye drops for delivering drugs topically lens hindered. The advancements nanomedicine present novel promising strategies addressing challenges drug delivery lens, development nanoparticle formulations that can improve penetration into anterior segment enable sustained release medications. This review introduces various cutting-edge systems cataract treatment, highlighting their physicochemical properties surface engineering optimal design, thus providing impetus further innovative research potential clinical applications anti-cataract drugs. Keywords: nanomedicine, cataract, ocular barrier, system
Язык: Английский
Процитировано
9
Angewandte Chemie International Edition, Год журнала: 2024, Номер 64(1)
Опубликована: Авг. 23, 2024
Chalcogens are used as sensitive redox-responsive reagents in tumor therapy. However, chalcogen bonds triggered by external ionizing radiation, rather than internal environmental stimuli, enable site-directed and real-time drug degradation target lesions. This approach helps to bypass chemoresistance global systemic toxicity, presenting a significant advancement over traditional chemoradiotherapy. In this study, we fabricated hybrid monodisperse organosilica nanoprodrug based on homonuclear single (disulfide (S-S, approximately 240 kJ/mol), diselenium (Se-Se, 172 tellurium (Te-Te, 126 kJ/mol)), including ditelluride-bond-bridged MONs (DTeMSNs), diselenide-bond-bridged (DSeMSNs) disulfide-bond-bridged (DSMSNs). The results demonstrated that differences electronegativities atomic radii influenced their oxidation sensitivities reactivities. Tellurium, with the lowest electronegativity, showed highest sensitivity, followed selenium sulfur. DTeMSNs exhibited highly responsive cleavage upon exposure X-rays, resulting TeO
Язык: Английский
Процитировано
9
Smart Molecules, Год журнала: 2024, Номер unknown
Опубликована: Июнь 14, 2024
Abstract As a novel drug development paradigm, selective activation of prodrugs provides the potential for precise tumor chemotherapy, thereby presenting an opportunity advancing cancer treatment. The combination photodynamic therapy (PDT) and prodrug can enhance therapeutic efficacy while simultaneously enabling real‐time monitoring distribution release. However, hypoxia microenvironment frequent high‐dose administration significantly impede escalate treatment‐related risks. Herein, microenvironment‐specific release is constructed, termed NBS‐2S‐5FU. Under influence glutathione (GSH), NBS‐2S‐5FU undergoes activation, leading to photosensitizer NBS chemotherapeutic agent 5‐FU derivatives. irradiation, produces sufficient superoxide radical () derivatives inhibit DNA biosynthesis, effectively suppressing growth at low doses. Subsequent in vivo studies utilizing liposomes exhibit outstanding anti‐cancer effectiveness. This study highlights promising direction combined that integrate PDT chemotherapy.
Язык: Английский
Процитировано
7
Journal of Medicinal Chemistry, Год журнала: 2023, Номер 66(24), С. 16546 - 16567
Опубликована: Дек. 12, 2023
Time- and space-resolved drug delivery is highly demanded for cancer treatment, which, however, can barely be achieved with a traditional prodrug strategy. In recent years, the strategy based on bioorthogonal bond cleavage chemistry has emerged advantages of high temporospatial resolution over activation homogeneous irrespective individual heterogeneity. past five tremendous progress been witnessed in this field one such entering Phase II clinical trials. This Perspective aims to highlight these new advances (2019–2023) critically discuss their pros cons. addition, remaining challenges potential strategic directions future will also included.
Язык: Английский
Процитировано
14
Science Bulletin, Год журнала: 2024, Номер 69(17), С. 2745 - 2755
Опубликована: Июль 15, 2024
Язык: Английский
Процитировано
6